Literature DB >> 8057132

Survival following interstitial brachytherapy for recurrent malignant glioma.

N D Kitchen1, S W Hughes, N A Taub, A Sofat, R P Beaney, D G Thomas.   

Abstract

The treatment of recurrent malignant glioma is difficult and at present largely disappointing. Furthermore the results of any treatment modality need to be interpreted with knowledge regarding patient selection and timing of treatment. The results of interstitial brachytherapy using iodine-125 in 23 patients are presented. There were no operative complications. Median survival time from tumour recurrence and implantation was 36 and 25 weeks respectively. Karnofsky Performance Status (KPS) was significantly associated with survival, though patient age, original tumour histology, prior chemotherapy, and time to recurrence were not. Treatment does confer modest survival benefit as compared to controls, but our results are not as impressive as others. Reasons for this finding are discussed.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8057132     DOI： 10.1007/bf01324601

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  9 in total

1.  Interstitial brachytherapy for malignant brain tumors: preliminary results.

Authors:  M Bernstein; N Laperriere; P Leung; S McKenzie
Journal:  Neurosurgery       Date:  1990-03       Impact factor: 4.654

2.  A coaxial catheter system for afterloading radioactive sources for the interstitial irradiation of brain tumors. Technical note.

Authors:  P H Gutin; R H Dormandy
Journal:  J Neurosurg       Date:  1982-05       Impact factor: 5.115

3.  Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma.

Authors:  J S Loeffler; E Alexander; P Y Wen; W M Shea; C N Coleman; H M Kooy; H A Fine; L A Nedzi; B Silver; N E Riese
Journal:  J Natl Cancer Inst       Date:  1990-12-19       Impact factor: 13.506

4.  Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas.

Authors:  S A Leibel; P H Gutin; W M Wara; P S Silver; D A Larson; M S Edwards; S A Lamb; B Ham; K A Weaver; C Barnett
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-12       Impact factor: 7.038

5.  Stereotactic brachytherapy for malignant glioma using a relocatable frame.

Authors:  A Sofat; S Hughes; J Briggs; R P Beaney; D G Thomas
Journal:  Br J Neurosurg       Date:  1992       Impact factor: 1.596

6.  Selection bias, survival, and brachytherapy for glioma.

Authors:  R C Florell; D R Macdonald; W D Irish; M Bernstein; S A Leibel; P H Gutin; J G Cairncross
Journal:  J Neurosurg       Date:  1992-02       Impact factor: 5.115

7.  Iodine-125 interstitial irradiation for cerebral gliomas.

Authors:  C B Ostertag; F W Kreth
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

8.  Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources.

Authors:  P H Gutin; T L Phillips; W M Wara; S A Leibel; Y Hosobuchi; V A Levin; K A Weaver; S Lamb
Journal:  J Neurosurg       Date:  1984-01       Impact factor: 5.115
  9 in total
  3 in total

Review 1.  Brachytherapy for brain tumors.

Authors:  Todd W Vitaz; Peter C Warnke; Viviane Tabar; Philip H Gutin
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

Review 2.  Iodine-125 brachytherapy for brain tumours--a review.

Authors:  Silke B Schwarz; Niklas Thon; Katharina Nikolajek; Maximilian Niyazi; Joerg-Christian Tonn; Claus Belka; Friedrich-Wilhelm Kreth
Journal:  Radiat Oncol       Date:  2012-03-06       Impact factor: 3.481

3.  A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG).

Authors:  Maurizio Amichetti; Dante Amelio
Journal:  Cancers (Basel)       Date:  2011-10-28       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.